Esperoct®, a glycoPEGylated form of recombinant Factor VIII, temporarily replaces the missing coagulation Factor VIII needed for effective hemostasis in congenital hemophilia A patients.1,2
With Esperoct®, your hemophilia A patients may need up to 50% fewer infusions per yeara compared to standard half-life (SHL) dosing regimens.
a50% fewer for adults and adolescents if previously dosed every other day; 40% fewer if previously dosed 3x/week.
ESPEROCT® MECHANISM OF ACTION
Extending half-life through PEGylation.
Esperoct® extends half-life by conjugating a 40-kDa polyethylene glycol residue to an O-linked glycan in the truncated B-domain of rFVIII.1,2,3